Steeghs, Neeltje
The Netherlands Cancer Institute
11 papers on CoChatORCID 0000-0003-2989-2279
Most cited papers
- Verified
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 1,491
- Verified
Pan-cancer whole-genome analyses of metastatic solid tumours
Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al. (2019) · Nature
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 1,106
- Verified
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 569
- Verified
The mutational footprints of cancer therapies
Pich, O., Muiños, F., Lolkema, M. P., Steeghs, N., Gonzalez-Perez, A., & Lopez-Bigas, N. (2019) · Nature Genetics
Cancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers
Cited by 309
- Verified
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
Meric-Bernstam, F., Sandhu, S. K., Hamid, O., Spreafico, A., Kasper, S., Dummer, R., Shimizu, T., Steeghs, N., Lewis, N., Talluto, C. C., et al. (2019) · Journal of Clinical Oncology
Cancer Immunotherapy and Biomarkersinterferon and immune responses
Cited by 190
- Verified
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Segal, N. H., Melero, I., Moreno, V., Steeghs, N., Marabelle, A., Rohrberg, K., Rodriguez-Ruiz, M. E., Eder, J. P., Eng, C., Manji, G. A., et al. (2024) · Nature Communications
Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research
Cited by 80
- Verified
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors
Brana, I., Shapiro, G., Johnson, M. L., Yu, H. A., Robbrecht, D., Tan, D. S.-W., Siu, L. L., Minami, H., Steeghs, N., Hengelage, T., et al. (2021) · Journal of Clinical Oncology
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 79
- Verified
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., et al. (2020) · British Journal of Cancer
Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies
Cited by 55
- Verified
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
Cassier, P. A., Dooms, C. A., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F. G., Solomon, B. J., Schuler, M. H., Tan, D. S.-W., et al. (2023) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 35
- Verified
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer
Brummelen, E. M. J., Huijberts, S., Herpen, C., Desar, I., Opdam, F., Geel, R., Marchetti, S., Steeghs, N., Monkhorst, K., Thijssen, B., et al. (2021) · The Oncologist
Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies
Cited by 32
- Verified
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer
Van Cutsem, E., Yaeger, R., Delord, J.-P., Tabernero, J., Siu, L. L., Ducreux, M., Siena, S., Elez, E., Kasper, S., Zander, T., et al. (2023) · The Oncologist
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free